← The Wire
CLDXNasdaq
Celldex Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · DE · CIK 744218
Develops therapeutic antibodies targeting mast cell biology for severe inflammatory and allergic diseases
red 8-K · 90d
$2.45B
Market cap
$37.44
Last close
+6.2%
1D
+12.1%
5D
1.6M
Volume
Price · last 39 sessions+14.3%
May 4L $28.56 · H $37.44Jun 29
373
Total filings
Jun 26, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 26, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEF 14AFORM DEF 14AApr 29, 2026424B5424B5Apr 2, 20268-KMaterial Agreement · Company UpdateApr 2, 2026424B5424B5Apr 1, 202610-K10-KFeb 25, 20268-KResults of OperationsFeb 25, 202610-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KCompany UpdateAug 19, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KExecutive Change · Shareholder VoteJun 6, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEF 14AFORM DEF 14AApr 21, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 202510-Q10-QNov 6, 20248-KResults of OperationsNov 6, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KExecutive Change · Shareholder VoteJun 14, 202410-Q10-QMay 6, 20248-KResults of OperationsMay 6, 2024DEF 14ADEF 14AApr 25, 20248-KMaterial Agreement · Company UpdateMar 1, 2024424B5424B5Mar 1, 2024424B5424B5Feb 28, 2024424B5424B5Feb 26, 202410-K10-KFeb 26, 20248-KResults of OperationsFeb 26, 2024SC 13GKYNAM CAPITAL MANAGEMENT, LPFeb 14, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GFeb 13, 2024SC 13GCELLDEX THERAPEUTICS, INC.Nov 20, 20238-KMaterial Agreement · Company UpdateNov 8, 2023424B5424B5Nov 8, 2023424B5424B5Nov 7, 20238-KCompany UpdateNov 6, 202310-Q10-QNov 2, 20238-KResults of OperationsNov 2, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KShareholder VoteJun 15, 202310-QFORM 10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEF 14ADEF 14AApr 25, 20238-KCompany UpdateMar 22, 202310-KFORM 10-KFeb 28, 20238-KResults of OperationsFeb 28, 20238-KExecutive Change · Reg FD DisclosureFeb 21, 2023SC 13GSEC SCHEDULE 13GFeb 6, 202310-QFORM 10-QNov 9, 20228-KResults of OperationsNov 9, 202210-QFORM 10-QAug 8, 20228-KResults of OperationsAug 8, 20228-KMaterial AgreementJul 18, 20228-KMaterial Agreement · Results of OperationsJun 23, 20228-KShareholder VoteJun 16, 2022SC 13GSC 13GJun 10, 202210-Q10-QMay 5, 20228-KResults of OperationsMay 5, 2022DEF 14ADEF 14AApr 26, 202210-KFORM 10KFeb 28, 20228-KResults of OperationsFeb 28, 2022SC 13GSC 13GFeb 10, 2022SC 13GSCHEDULE 13GFeb 9, 2022SC 13GSC 13GFeb 4, 20228-KBylaw AmendmentJan 28, 202210-Q10-QNov 9, 20218-KResults of OperationsNov 9, 2021SC 13GSC 13GOct 12, 202110-Q10-QAug 5, 20218-KResults of OperationsAug 5, 2021424B5424B5Jul 15, 20218-KMaterial Agreement · Company UpdateJul 14, 2021424B5424B5Jul 12, 2021
Insider Activity
In the 90 days to Dec 4, 2025: 2 sold $1.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 4, 2025 | Jimenez Freddy A.SVP & GENERAL COUNSEL | Sell | 4,166 | $29.10 | $121K |
| Nov 13, 2025 | Wright Richard M.Other | Sell | 49,298 | $24.00 | $1.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance